257 related articles for article (PubMed ID: 24597542)
1. The role of tigecycline in the treatment of infections in light of the new black box warning.
Dixit D; Madduri RP; Sharma R
Expert Rev Anti Infect Ther; 2014 Apr; 12(4):397-400. PubMed ID: 24597542
[TBL] [Abstract][Full Text] [Related]
2. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
[TBL] [Abstract][Full Text] [Related]
3. Tigecycline: an update.
Stein GE; Babinchak T
Diagn Microbiol Infect Dis; 2013 Apr; 75(4):331-6. PubMed ID: 23357291
[TBL] [Abstract][Full Text] [Related]
4. Establishing the role of tigecycline in an era of antimicrobial resistance.
Schafer JJ; Goff DA
Expert Rev Anti Infect Ther; 2008 Oct; 6(5):557-67. PubMed ID: 18847395
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections.
Bradford PA; Weaver-Sands DT; Petersen PJ
Clin Infect Dis; 2005 Sep; 41 Suppl 5():S315-32. PubMed ID: 16080070
[TBL] [Abstract][Full Text] [Related]
6. Tigecycline: a critical update.
Shakil S; Akram M; Khan AU
J Chemother; 2008 Aug; 20(4):411-9. PubMed ID: 18676218
[TBL] [Abstract][Full Text] [Related]
7. Therapy of 1,025 severely ill patients with complicated infections in a German multicenter study: safety profile and efficacy of tigecycline in different treatment modalities.
Bodmann KF; Heizmann WR; von Eiff C; Petrik C; Löschmann PA; Eckmann C
Chemotherapy; 2012; 58(4):282-94. PubMed ID: 23052187
[TBL] [Abstract][Full Text] [Related]
8. Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii.
Schafer JJ; Goff DA; Stevenson KB; Mangino JE
Pharmacotherapy; 2007 Jul; 27(7):980-7. PubMed ID: 17594203
[TBL] [Abstract][Full Text] [Related]
9. Tigecycline-induced acute pancreatitis: case report and literature review.
Hung WY; Kogelman L; Volpe G; Iafrati M; Davidson L
Int J Antimicrob Agents; 2009 Nov; 34(5):486-9. PubMed ID: 19540093
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections.
Falagas ME; Vardakas KZ; Tsiveriotis KP; Triarides NA; Tansarli GS
Int J Antimicrob Agents; 2014 Jul; 44(1):1-7. PubMed ID: 24602499
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic and pharmacodynamic evaluation of tigecycline.
Giamarellou H; Poulakou G
Expert Opin Drug Metab Toxicol; 2011 Nov; 7(11):1459-70. PubMed ID: 21958044
[TBL] [Abstract][Full Text] [Related]
12. Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms.
Garrison MW; Neumiller JJ; Setter SM
Clin Ther; 2005 Jan; 27(1):12-22. PubMed ID: 15763603
[TBL] [Abstract][Full Text] [Related]
13. Tigecycline: a new glycylcycline for treatment of serious infections.
Noskin GA
Clin Infect Dis; 2005 Sep; 41 Suppl 5():S303-14. PubMed ID: 16080069
[TBL] [Abstract][Full Text] [Related]
14. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia.
Freire AT; Melnyk V; Kim MJ; Datsenko O; Dzyublik O; Glumcher F; Chuang YC; Maroko RT; Dukart G; Cooper CA; Korth-Bradley JM; Dartois N; Gandjini H;
Diagn Microbiol Infect Dis; 2010 Oct; 68(2):140-51. PubMed ID: 20846586
[TBL] [Abstract][Full Text] [Related]
15. Re-defining tigecycline therapy.
De Rosa FG; Corcione S; Di Perri G; Scaglione F
New Microbiol; 2015 Apr; 38(2):121-36. PubMed ID: 25915055
[TBL] [Abstract][Full Text] [Related]
16. Clinical experience with tigecycline as treatment for serious infections in elderly and critically ill patients.
Kuo SC; Wang FD; Fung CP; Chen LY; Chen SJ; Chiang MC; Hsu SF; Liu CY
J Microbiol Immunol Infect; 2011 Feb; 44(1):45-51. PubMed ID: 21531352
[TBL] [Abstract][Full Text] [Related]
17. Use of tigecycline in critically ill patients with serious nosocomial intra-abdominal infections.
Maseda E; Denis SE; Riquelme A; Gilsanz F
Rev Esp Quimioter; 2013 Mar; 26(1):56-63. PubMed ID: 23546465
[TBL] [Abstract][Full Text] [Related]
18. Tigecycline: first of a new class of antimicrobial agents.
Rose WE; Rybak MJ
Pharmacotherapy; 2006 Aug; 26(8):1099-110. PubMed ID: 16863487
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial.
Sacchidanand S; Penn RL; Embil JM; Campos ME; Curcio D; Ellis-Grosse E; Loh E; Rose G
Int J Infect Dis; 2005 Sep; 9(5):251-61. PubMed ID: 16099700
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic applications of tigecycline in the management of complicated skin and skin structure infections.
Grolman DC
Int J Infect Dis; 2007 May; 11 Suppl 1():S7-15. PubMed ID: 17603950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
